All G Co Update
Agronomics Limited
27 November 2024
Agronomics Ltd
("Agronomics" or the "Company")
All G Receives Approval for Sale of Recombinant Bovine Lactoferrin in China
Agronomics (LSE: ANIC), a leading listed company in the field of cellular agriculture, is delighted to announce that its portfolio company, All G Co Holdings Pty Limited ("All G"), is the first company in the world to receive regulatory clearance for the sale of recombinant bovine lactoferrin in China.
All G is an Australian-based biotechnology company at the forefront of using precision fermentation to develop high-value, animal-free proteins for use in a variety of markets - ranging from functional foods, medical nutrition and infant nutrition.
Lactoferrin, a whey protein found in human and cow milk, is highly sought-after for its numerous functional benefits, including enhancing gut function, iron absorption and providing antimicrobial and anti-inflammatory benefits. However, due to its low concentration in cow's milk, it is expensive to produce and yields only limited quantities, creating a major opportunity for alternative protein producers.
China represents one of the largest consumers of lactoferrin globally, driven by a growing demand for functional foods and health-conscious consumers. The approval allows for the sale of All G's product into a specific target market which will be disclosed closer to the time of market entry. The company is simultaneously progressing with regulatory approval for the use of its lactoferrin in infant formula, which is expected in 2025.
This approval is significant for All G, as it will allow the company to bring in initial revenue streams in advance of its Series B fund raise. Revenues are projected to be at positive margins as All G aims to produce at or below price parity compared with conventionally produced lactoferrin. All G intends to release its first lactoferrin product in 2025 and plans to receive approval for its products in the US, Australia, New Zealand, and Japan.
All G's regulatory approval in China comes after only three years of operations. To date, All G has raised AU$ 45 million and was named Food & Beverage Startup of the Year by the Food and Beverage Accelerator in Australia for its work in changing dairy protein production. Agronomics has invested AU$ 15 million into All G since inception, which is currently carried at £7.9 million as of 30 June 2024.
Commenting on the announcement, Jan Pacas, All G CEO, said: "This approval is a great moment for All G as we lead the way in precision fermentation technology. Lactoferrin is one of the most valuable and functional proteins in the world. Our technology unlocks its potential, and this is just the beginning - our recombinant human lactoferrin is progressing rapidly, with many other products in the pipeline."
Jim Mellon, Agronomics' Executive Chair, added: "Today's announcement is another testament to the strength of the Agronomics portfolio. All G is one of the leading technology companies developing animal-free proteins and achieving regulatory approval for Lactoferrin in China - the world's largest market - is an exciting step for the industry. More importantly, it provides a platform from which All G can bring other key products to market at competitive prices."
About All G
All G is a Sydney-based biotechnology company that is at the forefront of precision fermentation, developing high-value, animal-free proteins for use in functional foods, medical nutrition and infant nutrition. Founded in 2020 by CEO Jan Pacas, the company has successfully raised AU$ 45 million and is planning to launch its first lactoferrin product in 2025.
About Agronomics
Agronomics is a leading London-listed company focussing on investment opportunities within the field of cellular agriculture. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.
For further information please contact:
|
Agronomics Limited |
Beaumont Cornish Limited |
Canaccord Genuity Limited |
Cavendish Securities Plc |
Peterhouse Capital Limited |
SEC Newgate |
|
The Company |
Nomad |
Joint Broker |
Joint Broker |
Joint Broker |
Public Relations |
|
Jim Mellon Denham Eke |
Roland Cornish James Biddle |
Andrew Potts Harry Pardoe Alex Aylen (Head of Equities) |
Giles Balleny Michael Johnson |
Lucy Williams Charles Goodfellow |
Bob Huxford Anthony Hughes |
|
+44 (0) 1624 639396 |
+44 (0) 207 628 3396 |
+44 (0) 207 523 8000 |
+44 (0) 207 397 8900 |
+44 (0) 207 469 0936 |
agronomics@secnewgate.co.uk |
Nominated Adviser
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 4 hours ago Johnson Matthey
- 5 hours ago Galliford Try
- 5 hours ago Galliford Try
- 5 hours ago Centrica
- 6 hours ago Smith & Nephew